\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ physical\\ exam\\ or\\ laboratory\\ findings\\ available\\.\ \(0\)\
\-\ the\\ patient\\ was\\ treated\\ with\\ a\\ whipple\\ procedure\\.\ \(0\)\
\-\ us\\ findings\\:\\ \\ the\\ common\\ bile\\ duct\\ measures\\ 14mm\\ with\\ this\\ pancreatic\\ parenchymal\\ tissue\\ and\\ pancreatic\\ duct\\ dilatation\\,\\ measuring\\ 5mm\\ in\\ diameter\\.\\ \\ these\\ findings\\ were\\ concerning\\ for\\ mucinous\\ duct\\ ecstatic\\ pancreatic\\ carcinoma\\ vs\\.\\ pancreatic\\ head\\ neoplasm\\.\ \(0\)\
\-\ ct\\ findings\\:\\ \\ a\\ 23\\ x\\ 21\\ mm\\ heterogeneous\\ mass\\ is\\ visualized\\ within\\ the\\ head\\ of\\ the\\ pancreas\\ with\\ moderate\\ dilatation\\ of\\ the\\ pancreatic\\ duct\\ as\\ well\\ as\\ marked\\ extra\\-\\ and\\ moderate\\ intra\\-hepatic\\ ductal\\ dilatation\\.\\ \\ the\\ sma\\ and\\ smv\\ fat\\ planes\\ appear\\ preserved\\.\ \(0\)\
\-\ pancreatic\\ adenocarinoma\\,\\ well\\-to\\-moderately\\ differentiated\\.\ \(0\)\
\-\ pancreatic\\ adenocarcinoma\ \(3\)\
\-\ mucinous\\ duct\\ ectatic\\ pancreatic\\ carcinoma\ \(0\)\
\-\ lymphoma\ \(373\)\
\-\ cholecystitis\ \(124\)\
\-\ 60yo\\ female\\ with\\ history\\ of\\ abdominal\\ lymphoma\\ presents\\ to\\ the\\ er\\ with\\ abdominal\\ pain\\.\ \(0\)\
\-\ pancreatic\\ adenocarcinoma\\ accounts\\ for\\ 3\\%\\ of\\ all\\ cancers\\ and\\ is\\ commonly\\ unresectable\\ at\\ time\\ of\\ presentation\\ giving\\ an\\ average\\ survival\\ time\\ of\\ 5\\-8\\ months\\.\\ \\ when\\ assessing\\ the\\ lesion\\ radiographically\\,\\ care\\ must\\ be\\ taken\\ to\\ determine\\ respectability\\,\\ as\\ surgery\\ \\(i\\.e\\.\\ whipple\\ procedure\\)\\ is\\ the\\ only\\ hope\\ of\\ cure\\.\\ \\ \ \(0\)\
\-\ sonographically\\,\\ adenocarcinoma\\ appears\\ as\\ a\\ hypoechoic\\ mass\\ or\\ just\\ a\\ subtle\\ alteration\\ of\\ echotexture\\ of\\ the\\ pancreas\\.\\ \\ biliary\\ and\\ pancreatic\\ ductal\\ dilatation\\ can\\ easily\\ be\\ identified\\ and\\ may\\ be\\ the\\ only\\ abnormality\\ identified\\.\\ \\ characteristically\\,\\ the\\ dilated\\ ducts\\ will\\ terminate\\ into\\ a\\ hypoechoic\\ mass\\.\\ \\ if\\ the\\ portal\\ vein\\,\\ superior\\ mesenteric\\ artery\\,\\ superior\\ mesenteric\\ vein\\,\\ hepatic\\ artery\\ or\\ celiac\\ trunk\\ are\\ seen\\ to\\ be\\ encased\\ in\\ tumor\\ or\\ involved\\ with\\ direct\\ tumor\\ invasion\\,\\ the\\ lesion\\ is\\ determined\\ to\\ be\\ non\\-resectable\\.\\ \\ also\\,\\ if\\ liver\\ or\\ peritoneal\\ metastases\\ are\\ identified\\,\\ the\\ lesion\\ is\\ not\\ resectable\\.\\ \ \(0\)\
\-\ on\\ ct\\,\\ pancreatic\\ adenocarcinoma\\ appears\\ as\\ a\\ hypodense\\ mass\\ distorting\\ the\\ contour\\ of\\ the\\ pancreas\\ with\\ common\\ bile\\ duct\\ and\\ pancreatic\\ duct\\ dilatation\\ and\\ possible\\ atrophy\\ of\\ the\\ remaining\\ pancreatic\\ tissue\\.\\ \\ criteria\\ for\\ non\\-resectability\\ on\\ ct\\ include\\ extension\\ of\\ the\\ tumor\\ beyond\\ the\\ margins\\ of\\ the\\ pancreas\\,\\ tumor\\ involvement\\ of\\ adjacent\\ organs\\,\\ enlarged\\ regional\\ lymph\\ nodes\\ \\(\\>15mm\\)\\,\\ encasement\\ or\\ involvement\\ of\\ peripancreatic\\ vessels\\,\\ metastases\\ in\\ the\\ liver\\,\\ or\\ peritoneal\\ carcinomatosis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pancreatic\\:\\ 0\\.1461028566252129\ \(0\)\
\-\ duct\\:\\ 0\\.07371975905405674\ \(0\)\
\-\ dilatation\\:\\ 0\\.04922347889070859\ \(0\)\
\-\ pancreas\\:\\ 0\\.047020077069636367\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.03969413381250795\ \(0\)\
\-\ whipple\\:\\ 0\\.03621546710906808\ \(0\)\
\-\ mucinous\\:\\ 0\\.027562575106734204\ \(0\)\
\-\ identified\\:\\ 0\\.024624734203115495\ \(0\)\
\-\ bile\\:\\ 0\\.02455388807482333\ \(0\)\
\-\ peritoneal\\:\\ 0\\.02390360522311547\ \(0\)\
\-\ well\\-to\\-moderately\\:\\ 0\\.023697630171952953\ \(0\)\
\-\ respectability\\:\\ 0\\.023697630171952953\ \(0\)\
\-\ terminate\\:\\ 0\\.023697630171952953\ \(0\)\
\-\ non\\-resectability\\:\\ 0\\.023697630171952953\ \(0\)\
\-\ extra\\-\\:\\ 0\\.021834331299479984\ \(0\)\
\-\ intra\\-hepatic\\:\\ 0\\.021834331299479984\ \(0\)\
\-\ 60yo\\:\\ 0\\.021834331299479984\ \(0\)\
\-\ ductal\\:\\ 0\\.021656057425722866\ \(0\)\
\-\ tumor\\:\\ 0\\.021421852705492597\ \(0\)\
\-\ mesenteric\\:\\ 0\\.021184522047125523\ \(0\)\
\-\ hypoechoic\\:\\ 0\\.020943749989991257\ \(0\)\
\-\ ecstatic\\:\\ 0\\.02074437133144728\ \(0\)\
\-\ adenocarinoma\\:\\ 0\\.02074437133144728\ \(0\)\
\-\ distorting\\:\\ 0\\.02074437133144728\ \(0\)\
\-\ 14mm\\:\\ 0\\.019971032427007013\ \(0\)\
\-\ non\\-resectable\\:\\ 0\\.019971032427007013\ \(0\)\
\-\ metastases\\:\\ 0\\.0196275938174354\ \(0\)\
\-\ findings\\:\\ 0\\.019557386406343653\ \(0\)\
\-\ 5\\-8\\:\\ 0\\.019371184170786017\ \(0\)\
\-\ encased\\:\\ 0\\.019371184170786017\ \(0\)\
\-\ procedure\\:\\ 0\\.019242346565250267\ \(0\)\
\-\ unresectable\\:\\ 0\\.01888107245897431\ \(0\)\
\-\ or\\:\\ 0\\.018845858179424604\ \(0\)\
\-\ resectable\\:\\ 0\\.018466688911051573\ \(0\)\
\-\ 15mm\\:\\ 0\\.018466688911051573\ \(0\)\
\-\ smv\\:\\ 0\\.01810773355453404\ \(0\)\
\-\ hope\\:\\ 0\\.01810773355453404\ \(0\)\
\-\ moderate\\:\\ 0\\.018065576928004284\ \(0\)\
\-\ be\\:\\ 0\\.017711783915913028\ \(0\)\
\-\ ectatic\\:\\ 0\\.017507885298313045\ \(0\)\
\-\ peripancreatic\\:\\ 0\\.017507885298313045\ \(0\)\
\-\ as\\:\\ 0\\.017373353573845805\ \(0\)\
\-\ cure\\:\\ 0\\.01725167513754873\ \(0\)\
\-\ appears\\:\\ 0\\.017100692584931444\ \(0\)\
\-\ involvement\\:\\ 0\\.016838379874343102\ \(0\)\
\-\ encasement\\:\\ 0\\.016802605017486455\ \(0\)\
\-\ vein\\:\\ 0\\.016623297430183426\ \(0\)\
\-\ sonographically\\:\\ 0\\.01624443468206107\ \(0\)\
\-\ liver\\:\\ 0\\.01583990059587486\ \(0\)\
\-\ characteristically\\:\\ 0\\.015782471625806607\ \(0\)\
\-\ assessing\\:\\ 0\\.015644586425840074\ \(0\)\
\-\ alteration\\:\\ 0\\.0155134300705459\ \(0\)\
\-\ sma\\:\\ 0\\.015154474714028367\ \(0\)\
\-\ giving\\:\\ 0\\.01504473816961908\ \(0\)\
\-\ superior\\:\\ 0\\.014670665037925761\ \(0\)\
\-\ echotexture\\:\\ 0\\.014554626457807373\ \(0\)\
\-\ regional\\:\\ 0\\.014554626457807373\ \(0\)\
\-\ 5mm\\:\\ 0\\.014466481772799335\ \(0\)\
\-\ accounts\\:\\ 0\\.014466481772799335\ \(0\)\
\-\ trunk\\:\\ 0\\.014466481772799335\ \(0\)\
\-\ celiac\\:\\ 0\\.014140242909884637\ \(0\)\
\-\ carcinomatosis\\:\\ 0\\.014064514745995668\ \(0\)\
\-\ lesion\\:\\ 0\\.014036735693552052\ \(0\)\
\-\ cancers\\:\\ 0\\.013849346176980786\ \(0\)\
\-\ only\\:\\ 0\\.013814041174650193\ \(0\)\
\-\ artery\\:\\ 0\\.013680268774775264\ \(0\)\
\-\ preserved\\:\\ 0\\.013586877172776709\ \(0\)\
\-\ average\\:\\ 0\\.013405583407197321\ \(0\)\
\-\ beyond\\:\\ 0\\.013347771027571075\ \(0\)\
\-\ planes\\:\\ 0\\.013181439297146108\ \(0\)\
\-\ ducts\\:\\ 0\\.013181439297146108\ \(0\)\
\-\ organs\\:\\ 0\\.013181439297146108\ \(0\)\
\-\ lymphoma\\:\\ 0\\.01313010018488971\ \(0\)\
\-\ \\,\\:\\ 0\\.01309887413793326\ \(0\)\
\-\ head\\:\\ 0\\.013030114572977937\ \(0\)\
\-\ carcinoma\\:\\ 0\\.01302111650546165\ \(0\)\
\-\ time\\:\\ 0\\.012976350684082327\ \(0\)\
\-\ mass\\:\\ 0\\.012779150612339404\ \(0\)\
\-\ radiographically\\:\\ 0\\.012691327585334405\ \(0\)\
\-\ easily\\:\\ 0\\.012691327585334405\ \(0\)\
\-\ criteria\\:\\ 0\\.012560171230040232\ \(0\)\
\-\ if\\:\\ 0\\.012466362547207718\ \(0\)\
\-\ survival\\:\\ 0\\.01231562343916462\ \(0\)\
\-\ differentiated\\:\\ 0\\.012276944037411665\ \(0\)\
\-\ i\\.e\\:\\ 0\\.012276944037411665\ \(0\)\
\-\ hypodense\\:\\ 0\\.012238813298185977\ \(0\)\
\-\ cholecystitis\\:\\ 0\\.012201215873522697\ \(0\)\
\-\ portal\\:\\ 0\\.01209147932911341\ \(0\)\
\-\ concerning\\:\\ 0\\.012055873880860666\ \(0\)\
\-\ common\\:\\ 0\\.012022941999765576\ \(0\)\
\-\ determined\\:\\ 0\\.011986047304507814\ \(0\)\
\-\ remaining\\:\\ 0\\.011951802611557734\ \(0\)\
\-\ atrophy\\:\\ 0\\.0118516106900598\ \(0\)\
\-\ determine\\:\\ 0\\.011631403371597739\ \(0\)\
\-\ biliary\\:\\ 0\\.011601367617301704\ \(0\)\
\-\ abdominal\\:\\ 0\\.011483436764097394\ \(0\)\
\-\ parenchymal\\:\\ 0\\.011291392223454943\ \(0\)\
\-\ contour\\:\\ 0\\.011136262337377936\ \(0\)\
\-\ invasion\\:\\ 0\\.011061930263908823\ \(0\)\
\-\ 23\\:\\ 0\\.010919161916290682\ \(0\)\
\-\ tissue\\:\\ 0\\.010889361228239752\ \(0\)\
\-\ direct\\:\\ 0\\.010850524007674648\ \(0\)\
\-\ subtle\\:\\ 0\\.010551530364905227\ \(0\)\
\-\ must\\:\\ 0\\.010471874994995628\ \(0\)\
\-\ margins\\:\\ 0\\.010432915297945718\ \(0\)\
\-\ 21\\:\\ 0\\.010394512187065403\ \(0\)\
\-\ nodes\\:\\ 0\\.010375514425713005\ \(0\)\
\-\ measures\\:\\ 0\\.009829201948257982\ \(0\)\
\-\ diameter\\:\\ 0\\.009664415588409069\ \(0\)\
\-\ ct\\:\\ 0\\.009639545591871313\ \(0\)\
\-\ us\\:\\ 0\\.009635510234171805\ \(0\)\
\-\ involved\\:\\ 0\\.009635510234171805\ \(0\)\
\-\ just\\:\\ 0\\.0095927267521667\ \(0\)\
\-\ hepatic\\:\\ 0\\.0095927267521667\ \(0\)\
\-\ taken\\:\\ 0\\.009578615580429755\ \(0\)\
\-\ appear\\:\\ 0\\.009401608683124413\ \(0\)\
\-\ visualized\\:\\ 0\\.009298204702404531\ \(0\)\
\-\ lymph\\:\\ 0\\.009272963464904966\ \(0\)\
\-\ vessels\\:\\ 0\\.009247957033017024\ \(0\)\
\-\ measuring\\:\\ 0\\.009186440114109531\ \(0\)\
\-\ vs\\:\\ 0\\.00904430099570107\ \(0\)\
\-\ marked\\:\\ 0\\.00896472984038846\ \(0\)\
\-\ er\\:\\ 0\\.008812323002548285\ \(0\)\
\-\ commonly\\:\\ 0\\.008668095278106563\ \(0\)\
\-\ abnormality\\:\\ 0\\.008474618128576753\ \(0\)\
\-\ laboratory\\:\\ 0\\.008465300365199102\ \(0\)\
\-\ mm\\:\\ 0\\.008446761174180122\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.008446761174180122\ \(0\)\
\-\ dilated\\:\\ 0\\.00834701991019255\ \(0\)\
\-\ care\\:\\ 0\\.008285422438356862\ \(0\)\
\-\ extension\\:\\ 0\\.008199804626832402\ \(0\)\
\-\ the\\:\\ 0\\.008176032966343462\ \(0\)\
\-\ presentation\\:\\ 0\\.00791236729701904\ \(0\)\
\-\ enlarged\\:\\ 0\\.007837691049419372\ \(0\)\
\-\ neoplasm\\:\\ 0\\.007823001548150346\ \(0\)\
\-\ possible\\:\\ 0\\.007736511341086215\ \(0\)\
\-\ available\\:\\ 0\\.007722363034515584\ \(0\)\
\-\ \\>\\:\\ 0\\.007632170738356357\ \(0\)\
\-\ x\\:\\ 0\\.007578135310073864\ \(0\)\
\-\ is\\:\\ 0\\.007557671752482871\ \(0\)\
\-\ adjacent\\:\\ 0\\.007263000656274912\ \(0\)\
\-\ will\\:\\ 0\\.007186776931126727\ \(0\)\
\-\ fat\\:\\ 0\\.006986323448606542\ \(0\)\
\-\ treated\\:\\ 0\\.00687594310775231\ \(0\)\
\-\ when\\:\\ 0\\.006578847412946252\ \(0\)\
\-\ all\\:\\ 0\\.006497106154385191\ \(0\)\
\-\ include\\:\\ 0\\.006443960989328729\ \(0\)\
\-\ a\\:\\ 0\\.0063967709970742135\ \(0\)\
\-\ months\\:\\ 0\\.0062740357384141595\ \(0\)\
\-\ are\\:\\ 0\\.006262762755535493\ \(0\)\
\-\ \\:\\:\\ 0\\.006076746322530457\ \(0\)\
\-\ these\\:\\ 0\\.005978077128918925\ \(0\)\
\-\ for\\:\\ 0\\.0058799044245380246\ \(0\)\
\-\ physical\\:\\ 0\\.005635766853713007\ \(0\)\
\-\ surgery\\:\\ 0\\.005577954474086761\ \(0\)\
\-\ into\\:\\ 0\\.0054659310966658796\ \(0\)\
\-\ 3\\:\\ 0\\.005378966469641236\ \(0\)\
\-\ \\%\\:\\ 0\\.005358389874586042\ \(0\)\
\-\ were\\:\\ 0\\.005215823485725595\ \(0\)\
\-\ can\\:\\ 0\\.005210275141045886\ \(0\)\
\-\ well\\:\\ 0\\.005196454174646912\ \(0\)\
\-\ exam\\:\\ 0\\.005046327795563275\ \(0\)\
\-\ may\\:\\ 0\\.005038517120693881\ \(0\)\
\-\ female\\:\\ 0\\.004722473847978048\ \(0\)\
\-\ of\\:\\ 0\\.004697733903144694\ \(0\)\
\-\ presents\\:\\ 0\\.004692592192225608\ \(0\)\
\-\ to\\:\\ 0\\.00459213019831168\ \(0\)\
\-\ seen\\:\\ 0\\.004539321545880888\ \(0\)\
\-\ also\\:\\ 0\\.004528547294812235\ \(0\)\
\-\ within\\:\\ 0\\.004382073678457209\ \(0\)\
\-\ on\\:\\ 0\\.00389188716325499\ \(0\)\
\-\ \\(\\:\\ 0\\.0038836651948594655\ \(0\)\
\-\ and\\:\\ 0\\.003871161413596096\ \(0\)\
\-\ \\)\\:\\ 0\\.0038362241511468017\ \(0\)\
\-\ in\\:\\ 0\\.003398364759195604\ \(0\)\
\-\ not\\:\\ 0\\.003319405031564343\ \(0\)\
\-\ an\\:\\ 0\\.0031765184523783064\ \(0\)\
\-\ history\\:\\ 0\\.0031726197250190416\ \(0\)\
\-\ at\\:\\ 0\\.0031122665398699814\ \(0\)\
\-\ pain\\:\\ 0\\.0028053982998138033\ \(0\)\
\-\ was\\:\\ 0\\.002656660005950771\ \(0\)\
\-\ this\\:\\ 0\\.002583702186328315\ \(0\)\
\-\ no\\:\\ 0\\.0023130219104940913\ \(0\)\
\-\ patient\\:\\ 0\\.002302666480958032\ \(0\)\
\-\ with\\:\\ 0\\.0022016914855624414\ \(0\)\
\-\ \\.\\:\\ 0\\.0018131483490580087\ \(0\)\
